journal
Journals Recent Patents on Anti-cancer ...

Recent Patents on Anti-cancer Drug Discovery

https://read.qxmd.com/read/38305309/tpd52-as-a-potential-prognostic-biomarker-and-its-correlation-with-immune-infiltrates-in-uterine-corpus-endometrial-carcinoma-bioinformatic-analysis-and-experimental-verification
#21
JOURNAL ARTICLE
Lu Miao, Buze Chen, Li Jing, Tian Zeng, Youguo Chen
BACKGROUND: Aberrant expression of tumor protein D52 (TPD52) is associated with some tumors. The role of TPD52 in uterine corpus endometrial carcinoma (UCEC) remains uncertain. OBJECTIVE: We aimed to investigate the involvement of TPD52 in the pathogenesis of UCEC. METHODS: We employed bioinformatics analysis and experimental validation in our study. RESULTS: Our findings indicated that elevated TPD52 expression in UCEC was significantly associated with various clinical factors, including clinical stage, race, weight, body mass index (BMI), histological type, histological grade, surgical approach, and age (p < 0...
January 3, 2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38173209/exosome-derived-cargos-in-immune-microenvironment-in-esophageal-carcinoma-a-mini-review
#22
JOURNAL ARTICLE
Yakun Zhang, Xiaoyan Sun, Yan Guan, Ying Sun
Esophageal carcinoma, a lethal malignancy with limited treatment options and poor prognosis, necessitates understanding its underlying mechanisms and identifying novel therapeutic targets. Recent studies have highlighted the critical role of the immune microenvironment in esophageal carcinoma, particularly the interplay between tumor cells and immune cells mediated by exosomes and their cargos. Exosomes, small extracellular vesicles secreted by various cells, including tumor cells, facilitate intercellular communication by transferring bioactive molecules such as proteins, nucleic acids, and lipids to recipient cells...
January 3, 2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214361/pulmonary-adenocarcinoma-patient-with-complex-mutations-on-egfr-benefits-from-furmonertinib-after-acquiring-gefitinib-resistance-a-case-report
#23
Guixian Wu, Qian Chen, Dongqing Lv, Ling Lin, Jing Huang
BACKGROUND: Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been proven a long-lasting treatment effect in pulmonary adenocarcinoma, most patients still progressed within one year due to the acquired resistance. Complex mutations of rare rare sites after acquiring resistance are rarely reported in pulmonary adenocarcinoma. CASE PRESENTATION: A 62-year-old woman was diagnosed with pulmonary adenocarcinoma with stage IV. Genetic testing at the initial treatment showed EGFR L858R positive...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214360/circ_0070203-promotes-epithelial-mesenchymal-transition-in-ovarian-serous-cystadenocarcinoma-through-mir-370-3p-tgf%C3%AE-r2-axis
#24
JOURNAL ARTICLE
Qiong Tang, Huiting Wen, Haoyue Hu, Xiaoli Chen, Shuxiu Xu, Li Fan, Longyang Liu, Jing Li
INTRODUCTION: Circular RNAs (circRNAs) are important biological molecules associated with the pathogenesis of multiple cancers. OBJECTIVE: This work aimed to investigate the function and molecular mechanism of circ_0070203 in high-grade serous ovarian cystadenocarcinoma (HGSOC). METHODS: circRNA microarray was conducted to detect the circ_0070203 expression in HGSOC tissues. Bioinformatics analysis was used to find the binding sites between circ_0070203, miR- 370-3p and TGFβR2...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214359/a-synergistic-combination-of-oleanolic-acid-and-apatinib-to-enhance-antitumor-effect-on-liver-cancer-cells-and-protect-against-hepatic-injury
#25
JOURNAL ARTICLE
Juan Ren, Jun Yan, Faisal Raza, Hajra Zafar, Haopeng Wan, Xue Chen, Qingrong Cui, Haiyang Li, Xiangqi Wang
BACKGROUND: As a pentacyclic triterpenoid, OA (oleanolic acid) has exhibited antiinflammatory, immunomodulatory and antitumor effects. VEGFR-2 (vascular endothelial cells receptor-2) tyrosine kinase activity could be inhibited by apatinib, a small-molecule antiangiogenic agent. OBJECTIVE: Thus, this study sought to investigate the mechanism underlying the synergistic antitumor activity of combined OA and apatinib patent. METHODS: Through CCK8 (Cell counting kit 8 assay), flow cytometric and western blotting techniques, we conducted in vitro studies on apatinib and OA effects on cell proliferation and apoptosis in H22 cell line...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214358/human-chorionic-gonadotropin-regulates-the-smad-signaling-pathway-by-antagonizing-tgf-%C3%AE-in-giant-cell-tumor-of-bone
#26
JOURNAL ARTICLE
Tangbing Xu, Shenglin Xu, Guangwen Ma, Jun Chang, Chi Zhang, Ping Zhou, Chao Wang, Pengfei Xu, Junjun Yang, Yong Hu, Yunfeng Wu
BACKGROUND: Giant cell tumor of bone (GCTB) is a locally aggressive bone tumour aggravated by stromal cell proliferation and metastasis. OBJECTIVE: We investigated the mechanism of action of human chorionic gonadotropin (HCG) in mediating GCTB proliferation and invasion. METHODS: The expression of HCG was quantified using quantitative real-time PCR. After the primary stromal cells were isolated and identified, the function of HCG in GCTB was estimated using the cell counting kit-8, flow cytometry, scratch experiment, transwell assay, Western blot, and immunofluorescence...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214357/ybx1-targeted-by-microrna-382-5p-promotes-laryngeal-squamous-cell-carcinoma-progression-via-modulating-ras-mapk-signaling
#27
JOURNAL ARTICLE
Wen Zeng, Yiyun Pan, Hailong Chen, Xianhua Lei, Xiangmin Zhang
BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is the most common cancer of head and neck cancer. Y-box binding protein-1 (YBX1) has tumor-promoting effects in some types of cancers. However, its role in LSCC remains unknown. This study set out to identify the role of YBX1 in LSCC. METHODS: Bioinformatics analysis of the Gene Expression Omnibus (GEO) database and our cohort data were used to explore the association of YBX1 expression with clinicopathological factors in LSCC...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214356/the-fjqr-has-synergistic-effect-with-fluoropyrimidine-in-the-maintenance-treatment-for-her-2-negative-gastric-cancer
#28
JOURNAL ARTICLE
Fanming Kong, Lu Zhao, Na Wang, Dou Zhang, Ziwei Wang, Qingyun Mei, Yongchao Yu, Yingjie Jia
INTRODUCTION: Maintenance therapy aimed to strengthen the first-line chemotherapy and improve quality of life is needed for gastric cancer (GC). Currently, many clinical studies have confirmed the important role of fluoropyrimidine in the maintenance stage. Our team has created patented prescriptions "Fuzheng jiedu Quyu Method" recipe (FJQR), which was considered as an adjuvant therapeutic scheme (reduce toxicity and increase the efficacy of chemotherapy). This study aimed to evaluate the efficacy and safety of FJQR combined with fluoropyrimidine as a maintenance treatment in HER-2 negative GC patients...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214355/development-and-evaluation-of-a-novel-hyaluronic-acid-and-chitosan-modified-phytosome-for-co-delivery-of-oxymatrine-and-glycyrrhizin-for-combination-therapy
#29
JOURNAL ARTICLE
Xiaojin Chen, Shuying Yu, Pingping Wang, XinFeng Zhao, Gao Sang
BACKGROUND: Multidrug resistance (MDR) of cancer cells is a major obstacle to efficient cancer chemotherapy. Combination therapy is expected to enhance the anticancer effect and reverse MDR. Numerous patents involve different kinds of nanoparticles for the co-delivery of multiple chemotherapeutics, but the FDA has approved none. OBJECTIVE: In this study, oxymatrine (OMT) and glycyrrhizin (GL) were co-loaded into phytosomes as the core of nanocarriers, and the shell was cross-linked with chitosan (CS) and hyaluronic acid (HA) with the capability for the controlled, sequential release and the targeted drug uptake...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214354/chlorogenic-acid-inhibits-proliferation-migration-and-invasion-of-pancreatic-cancer-cells-via-akt-gsk-3%C3%AE-%C3%AE-catenin-signaling-pathway
#30
JOURNAL ARTICLE
Xiaoliang Chen, Binyu Liu, Jiale Tong, Jianing Bo, Miao Feng, Lili Yin, Xiukun Lin
BACKGROUND: Chlorogenic acid (CA, United States Patent No. 10772340), a natural biologically active food ingredient, displays potent antitumor activity against a variety of cancer cells. However, the mechanism underlying its anticancer effect is not well elucidated. OBJECTIVE: In the present study, we hope to dissect the mechanism underlying the anticancer effects of CA in pancreatic cancer cells. METHODS: The cytotoxicity of CA in pancreatic cancer cells was determined by MTT assay...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214323/from-multiple-myeloma-to-acute-myeloid-leukemia-a-case-report-of-a-61-year-old-woman-after-8-years-of-chemotherapy-and-immunotherapy
#31
REVIEW
Xue-Hang Fu, Rong-Yan Guan, Zoufang Huang, Yun Li, Guang Lu, Wei-Wei Mou, Jun Du
BACKGROUND: As the second most prevalent hematologic malignancy, multiple myeloma (MM) affects plasma cells and is characterized by chromosomal abnormalities, particularly involving the immunoglobulin heavy chain switch region. MM represents a biologically and clinically heterogeneous hematological malignancy that serves as a clonal evolution model, exhibiting clonal heterogeneity throughout all stages from monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to MM...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214322/psma-pet-mr-is-a-new-imaging-option-for-identifying-glioma-recurrence-and-predicting-prognosis
#32
JOURNAL ARTICLE
Min Xiong, Zhenghe Chen, Chao Zhou, Xiaochun Yang, Wanming Hu, Yongluo Jiang, Rongliang Zheng, Wei Fan, Yonggao Mou, Xiaoping Lin
BACKGROUND: Glioma is characterized by a high recurrence rate, while the results of the traditional imaging methods (including magnetic resonance imaging, MRI) to distinguish recurrence from treatment-related changes (TRCs) are poor. Prostate-specific membrane antigen (PSMA) (US10815200B2, Deutsches Krebsforschungszentrum, German Cancer Research Center) is a type II transmembrane glycoprotein overexpressed in glioma vascular endothelium, and it is a promising target for imaging and therapy...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214321/integrated-single-cell-and-bulk-rna-sequencing-analysis-cross-talk-between-ferroptosis-related-genes-and-prognosis-in-oral-cavity-squamous-cell-carcinoma
#33
JOURNAL ARTICLE
Tianjun Lan, Siqi Ren, Huijun Hu, Ruixin Wang, Qian Chen, Fan Wu, Qiuping Xu, Yanyan Li, Libin Shao, Liansheng Wang, Xin Liu, Haotian Cao, Jinsong Li
BACKGROUND: Ferroptosis is a new type of programmed apoptosis and plays an important role in tumour inhibition and immunotherapy. OBJECTIVE: In this study, we aimed to explore the potential role of ferroptosis-related genes (FRGs) and the potential therapeutic targets in oral cavity squamous cell carcinoma (OCSCC). METHODS: The transcription data of OCSCC samples were obtained from the Cancer Genome Atlas (TCGA) database as a training dataset...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38214320/prognostic-value-of-fatty-acid-metabolism-related-genes-in-patients-with-bladder-cancer
#34
JOURNAL ARTICLE
Qiuzheng Huang, Zhijia Li, Chao Liu
INTRODUCTION: This study aimed to explore the expression profiles of fatty acid metabolism- related genes (FAMRGs) in patients with bladder cancer (BLCA). METHODS: The corresponding clinicopathological features of BLCA patients and RNA sequencing data were downloaded from TCGA and GSE13507. Univariate Cox regression was used to determine the prognostic value of FRGS in BLCA patients. LASSO regression analysis was then performed to select potential risk genes and eliminate genes that might overfit the model...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/37937574/optimal-rituximab-monotherapy-in-splenic-marginal-zone-lymphoma-smzl-a-case-report-and-brief-review
#35
Rong-Yan Guan, Xing-Ru Tang, Zou-Fang Huang, Jun Du, Xue-Hang Fu, Guang Lu, Wei-Wei Mou
INTRODUCTION: Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B lymphocyte proliferative disease. Generally, SMZL is accompanied by circulating atypical villous lymphocytes, known as SMZL with villous lymphocytes. Rituximab is a chimeric monoclonal antibody to CD20; recent but limited studies have confirmed its effectiveness in treating SMZL. Given the low incidence and selection of treatment, statistical comparisons of rituximab monotherapy with other available treatment options with the full range of data from previous clinical studies remain sparse...
November 3, 2023: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/37885107/intracholecystic-papillary-tubular-neoplasm-icpn-of-the-gallbladder-a-case-report-focusing-on-an-unexpected-pathological-finding
#36
Antonio Pesce, Valentina Sani, Alba Gaban, Nicolò Fabbri, Massimo Tilli, Roberta Gafà, Carlo Vittorio Feo
BACKGROUND: Intracholecystic papillary neoplasms (ICPNs) represent a rare benign entity characterized by intraluminal polypoid lesions in the gallbladder. The incidence of ICPNs ranges from 0.4% to 0.61% in all gallbladder specimens. CASE PRESENTATION: In this report, we present a case of a young Caucasian woman who underwent elective laparoscopic cholecystectomy due to gallbladder polyps. The histological examination revealed the presence of an intracholecystic papillary neoplasm (ICPN) with a tubulopapillary growth pattern, exhibiting gastric morphology and displaying both low and high-grade dysplasia...
October 25, 2023: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/37877147/targeted-regulation-of-osteoblasts-and-osteoclasts-in-osteosarcoma-patients-by-csf3r-receptor-inhibition-of-osteolysis-caused-by-tumor-inflammation-based-on-transcriptional-spectrum-analysis-and-drug-library-screening
#37
JOURNAL ARTICLE
Qian Li, Jinlu Shan, Wei Duan, Yu Chen
BACKGROUND: Osteosarcoma (OS) is a common primary malignant bone tumor that mainly occurs in children and adolescents. The use of IL-8 inhibitor compounds has been reported in patents, which can be used to treat and/or prevent osteosarcoma, but the pathogenesis of osteosarcoma remains to be investigated. At present, osteoblasts and osteoclasts play an important role in the occurrence and development of OS. However, the relationship between osteoblasts and osteoclasts in the specific participation mechanism and inflammatory response of OS patients has not been further studied...
October 18, 2023: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/37877146/upregulation-of-m6a-reader-hnrnpa2b1-associated-with-poor-prognosis-and-tumor-progression-in-lung-adenocarcinoma
#38
JOURNAL ARTICLE
Wei Wang, Shengwei Li
BACKGROUND: Lung cancer is the most prevalent malignancy worldwide, and lung adenocarcinoma (LUAD) accounts for a substantial proportion of all cases. N6-methyladenosine (m6A) is the most frequent post-transcriptional modification in mRNAs that also plays a role in cancer development. Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) is a reader of m6A modification, which can affect tumor invasion, migration, and proliferation. OBJECTIVES: The purpose of this study was to explore the prognostic factors of LUAD based on m6A through bioinformatics analysis...
October 17, 2023: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/37861020/matrix-metalloproteinase-2-mmp-2-as-an-essential-factor-in-cancer-progression
#39
JOURNAL ARTICLE
R Aishwarya Reddy, M Sai Varshini, R Suresh Kumar
The development of cancer has been a multistep process involving mutation, proliferation, survival, invasion, and metastasis. Of all the characteristics of cancer, metastasis is believed to be the hallmark as it is responsible for the highest number of cancer-related deaths. In connection with this, Matrix metalloproteinases (MMPs), that has a role in metastasis, are one of the novel therapeutic targets. MMPs belong to the family of zinc-dependent endopeptidases and are capable of degrading the components of the extracellular matrix (ECM)...
October 9, 2023: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/37818578/the-clinical-significance-and-prognostic-value-of-aldh1-expression-in-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#40
Dong Li, Yu Cao, Cheng-Wen Luo, Li-Ping Zhang, Ying-Bo Zou
BACKGROUND: The results of the association between aldehyde dehydrogenase 1 (ALDH1) expression and prognosis of non-small cell lung cancer (NSCLC) are contradictory. We conducted this meta-analysis to investigate the clinical significance and prognostic value of ALDH1 in NSCLC. METHODS: The databases PubMed, Web of Science, EMBASE, the Cochrane Library, Wanfang, and CNKI were systematically queried to identify eligible studies. The retrieval time was from database establishment to August 2023...
October 5, 2023: Recent Patents on Anti-cancer Drug Discovery
journal
journal
41278
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.